Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A Simplified and Efficient Process for Insulin Production in Pichia pastoris.

Polez S, Origi D, Zahariev S, Guarnaccia C, Tisminetzky SG, Skoko N, Baralle M.

PLoS One. 2016 Dec 1;11(12):e0167207. doi: 10.1371/journal.pone.0167207. eCollection 2016.

2.

Dual role of dextran sulfate 5000 Da as anti-apoptotic and pro-autophagy agent.

Menvielle JP, Safini N, Tisminetzky SG, Skoko N.

Mol Biotechnol. 2013 Jun;54(2):711-20. doi: 10.1007/s12033-012-9620-x.

PMID:
23180219
3.

Expression and characterization of human interferon-beta1 in the methylotrophic yeast Pichia pastoris.

Skoko N, Argamante B, Grujicić NK, Tisminetzky SG, Glisin V, Ljubijankić G.

Biotechnol Appl Biochem. 2003 Dec;38(Pt 3):257-65.

PMID:
12911337
4.

Mix-infections with different genotypes of HCV and with HCV plus other hepatitis viruses in patients with hepatitis C in China.

Chen YD, Liu MY, Yu WL, Li JQ, Dai Q, Zhou ZQ, Tisminetzky SG.

World J Gastroenterol. 2003 May;9(5):984-92.

5.

Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study.

Stanta G, Crocè LS, Bonin S, Tisminetzky SG, Baralle FE, Tiribelli C.

J Clin Virol. 2000 Jun;17(1):51-6.

PMID:
10814939
6.

Influence of correct secondary and tertiary RNA folding on the binding of cellular factors to the HCV IRES.

Odreman-Macchioli FE, Tisminetzky SG, Zotti M, Baralle FE, Buratti E.

Nucleic Acids Res. 2000 Feb 15;28(4):875-85.

7.

Immunoreactivity to putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic subjects.

Toniutto P, Fabris C, Barbone F, Tisminetzky SG, Liani D, Galai T, Barillari G, Biffoni F, Gasparini V, Pirisi M.

Clin Diagn Lab Immunol. 1999 Jul;6(4):573-6.

8.

IgM antibody response to the hepatitis C virus core protein in intravenous drug users.

Toniutto P, Falleti E, Gasparini V, Fabris C, Tisminetzky SG, Lombardelli T, Pacco P, Satta A, Pirisi M.

Diagn Microbiol Infect Dis. 1999 Feb;33(2):69-73.

PMID:
10091028
9.

Localization of the different hepatitis C virus core gene products expressed in COS-1 cells.

Buratti E, Baralle FE, Tisminetzky SG.

Cell Mol Biol (Noisy-le-grand). 1998 May;44(3):505-12.

PMID:
9620447
10.

Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug users.

Pirisi M, Toniutto P, Fabris C, Lombardelli T, Falleti E, Tisminetzky SG, Baralle F, Bartoli E.

J Clin Epidemiol. 1998 May;51(5):423-7.

PMID:
9619970
11.

High prevalence of infection with hepatitis G virus in patients with hepatic and extrahepatic malignancies.

Toniutto P, Pirisi M, Fabris C, Bardus P, Soardo G, Vitulli D, Tisminetzky SG, Pacco P, Gasparini V, Baralle F, Bartoli E.

J Hepatol. 1998 Apr;28(4):550-5.

PMID:
9566822
12.

In vivo translational efficiency of different hepatitis C virus 5'-UTRs.

Buratti E, Gerotto M, Pontisso P, Alberti A, Tisminetzky SG, Baralle FE.

FEBS Lett. 1997 Jul 14;411(2-3):275-80.

13.

Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

Pirisi M, Fabris C, Toniutto P, Falleti E, Tisminetzky SG, Gerotto M, Soardo G, Vitulli D, Del Forno M, Baralle F, Bartoli E.

Dig Dis Sci. 1997 Apr;42(4):767-71.

PMID:
9125646
14.

Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen-presenting system.

Buratti E, Di Michele M, Song P, Monti-Bragadin C, Scodeller EA, Baralle FE, Tisminetzky SG.

Clin Diagn Lab Immunol. 1997 Mar;4(2):117-21.

16.

V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.

Schiappacassi M, Buratti E, D'Agaro P, Ciani L, Scodeller ES, Tisminetzky SG, Baralle FE.

J Virol Methods. 1997 Jan;63(1-2):121-7.

PMID:
9015282
17.

Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House virus capsid protein.

Buratti E, Tisminetzky SG, Scodeller ES, Baralle FE.

J Immunol Methods. 1996 Oct 16;197(1-2):7-18.

PMID:
8890890
18.

Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regions.

Toniutto P, Pirisi M, Tisminetzky SG, Fabris C, Chinellato E, Gerotto M, Falleti E, Ferroni P, Lombardelli T, Bartoli E, Baralle F.

J Clin Microbiol. 1996 Oct;34(10):2382-5.

19.

A new epitope presenting system displays a HIV-1 V3 loop sequence and induces neutralizing antibodies.

Scodeller EA, Tisminetzky SG, Porro F, Schiappacassi M, De Rossi A, Chiecco-Bianchi L, Baralle FE.

Vaccine. 1995 Sep;13(13):1233-9.

PMID:
8578809
20.

Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF. Correlation between predicted conformation and antigenicity.

Tisminetzky SG, Scodeller EA, Evangelisti P, Chen Y, Schiappacassi M, Porro F, Bizik F, Zacchi T, Lunazzi G, Miertus S, et al.

FEBS Lett. 1994 Oct 10;353(1):1-4.

21.

Presence of a 43-kDa host-cell polypeptide in purified aphthovirions.

Grigera PR, Tisminetzky SG, Lebendiker MB, Periolo OH, La Torre JL.

Virology. 1988 Aug;165(2):584-8.

PMID:
2841802
22.

Histone H3 modification in BHK cells infected with foot-and-mouth disease virus.

Grigera PR, Tisminetzky SG.

Virology. 1984 Jul 15;136(1):10-9.

PMID:
6330987
23.

Heterogeneity of infection-associated particles in foot-and-mouth disease virus.

Vasquez C, Grigera PR, Tisminetzky SG, Denoya CD, La Torre JL.

Virology. 1981 Oct 30;114(2):370-8. No abstract available.

PMID:
6270879
24.

[Molecular biology of the foot-and-mouth disease virus].

Dubra MS, Lebendiker MA, Grigera PR, Tisminetzky SG, Costa Giomi MP, Sagedahl A, La Torre JL, Vázquez C.

Medicina (B Aires). 1981;41 Suppl:221-9. Spanish. No abstract available.

PMID:
6285123

Supplemental Content

Loading ...
Support Center